AssetMark Inc
CORT icon

AssetMark Inc’s Corcept Therapeutics CORT Stock Holding History

AssetMark Inc’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.07M Sell
35,288
-44,655
-56% -$2.7M 0.01% 855
2026
Q1 		$3.22M Sell
79,943
-2,155
-3% -$80.6K 0.01% 775
2025
Q4 		$2.86M Buy
82,098
+17,372
+27% +$1.36M 0.01% 774
2025
Q3 		$5.38M Buy
64,726
+2,961
+5% +$214K 0.01% 615
2025
Q2 		$4.53M Sell
61,765
-9,225
-13% -$669K 0.01% 606
2025
Q1 		$8.11M Buy
70,990
+14,413
+25% +$877K 0.02% 396
2024
Q4 		$2.85M Sell
56,577
-6,734
-11% -$353K 0.01% 634
2024
Q3 		$2.93M Buy
63,311
+1,235
+2% +$43.9K 0.01% 570
2024
Q2 		$2.02M Buy
62,076
+5,100
+9% +$140K 0.01% 615
2024
Q1 		$1.44M Buy
56,976
+875
+2% +$20.7K ﹤0.01% 648
2023
Q4 		$1.82M Buy
56,101
+38,674
+222% +$1.06M 0.01% 551
2023
Q3 		$475K Sell
17,427
-27,149
-61% -$786K ﹤0.01% 763
2023
Q2 		$992K Buy
44,576
+2,561
+6% +$58.9K ﹤0.01% 613
2023
Q1 		$910K Buy
42,015
+3,325
+9% +$72.9K ﹤0.01% 617
2022
Q4 		$786K Buy
38,690
+1,089
+3% +$27.3K ﹤0.01% 633
2022
Q3 		$964K Buy
37,601
+620
+2% +$16.6K ﹤0.01% 519
2022
Q2 		$879K Buy
36,981
+3,390
+10% +$73.9K ﹤0.01% 525
2022
Q1 		$756K Sell
33,591
-4,215
-11% -$89.7K ﹤0.01% 537
2021
Q4 		$749K Sell
37,806
-26,068
-41% -$529K ﹤0.01% 464
2021
Q3 		$1.26M Buy
63,874
+6,315
+11% +$132K 0.01% 374
2021
Q2 		$1.27M Buy
57,559
+29,258
+103% +$651K 0.01% 363
2021
Q1 		$673K Buy
28,301
+2,258
+9% +$60.3K ﹤0.01% 409
2020
Q4 		$681K Sell
26,043
-21,540
-45% -$454K ﹤0.01% 393
2020
Q3 		$828K Buy
47,583
+38,501
+424% +$614K 0.01% 348
2020
Q2 		$153K Buy
+9,082
New +$128K ﹤0.01% 526

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AssetMark Inc's CORT Position: Q2 2026 in Review

AssetMark Inc reduced its Corcept Therapeutics (CORT) stake by 56% in Q2 2026, selling an estimated $2.7M and leaving 35,288 shares worth $3.07M. The position accounts for 0.01% of the portfolio, ranked #855.

AssetMark Inc first reported a position in CORT in Q2 2020 and has held it in 25 quarters since. The position peaked at $8.11M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • AssetMark Inc held 35,288 shares of Corcept Therapeutics worth $3.07M as of Q2 2026.
  • AssetMark Inc sold 44,655 Corcept Therapeutics shares in Q2 2026, an estimated $2.7M.
  • Corcept Therapeutics made up 0.01% of AssetMark Inc's portfolio in Q2 2026, its #855 holding.
  • AssetMark Inc first reported a position in Corcept Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • AssetMark Inc's Corcept Therapeutics position peaked at $8.11M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.